Imatinib Mesylate 400mg Tablets from Japan
Imatinib mesylate tablets are an antineoplastic medicament used primarily for treating chronic myeloid leukemia by inhibiting tyrosine kinase activity. They are put up in measured doses of 400mg per tablet in retail packaging, qualifying under HTS 3004.90.92.16 as an unmixed antineoplastic product for therapeutic use.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.6215%Pharmaceuticals: patented pharma from JP/EU/KR/CH/LI — 15% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Verify FDA approval and provide certificates of analysis confirming active ingredient purity to avoid detention at customs
• Ensure labeling complies with 21 CFR 201 for prescription drugs, including lot numbers and expiry dates